US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
By Ahmed Aboulenein and Amina Niasse WASHINGTON (Reuters) -The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S. Federal Trade Commission said on Tuesday. From 2017 to 2022, the companies — UnitedHealth Group’s Optum, CVS Health’s…
